Switch to
More onapp

Laurus Labs Ltd

LAURUSLABS
Health CarePharmaceuticals
MidcapWith a market cap of ₹18,409 cr, stock is ranked 239
Low RiskStock is 1.96x as volatile as Nifty
341.850.35 (-0.10%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
MidcapWith a market cap of ₹18,409 cr, stock is ranked 239
Low RiskStock is 1.96x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
22.25
PB RatioPB Ratio
5.48
Dividend YieldDiv. Yield
0.58%
Sector PESector PE
34.15
Sector PBSector PB
4.18
Sector Div YldSctr Div Yld
0.92%

Forecast & RatingsDetailed Forecast 

55%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Laurus Labs Private Ltd is a research and development pharmaceutical company which manufactures active pharmaceutical ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Investor PresentationView older 

Oct 21, 2022

PDF
View Older Presentations

Financial TrendFinancial statements 

20192020202120222.312.844.844.950.090.260.980.83
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Analysts/Institutional Investor Meet/Con. Call Updates 
Announced OnJan 21, 2023

Laurus Labs Limited has informed the Exchange about Schedule of meet | Download

Laurus Labs Limited has informed the Exchange about Schedule of meet | Download

Updates 
Announced OnJan 20, 2023

Laurus Labs Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of the SEBI (Listing Obligations and DisclosureRequirements) Regulations, 2015'. | Download

Laurus Labs Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of the SEBI (Listing Obligations and DisclosureRequirements) Regulations, 2015'. | Download

Cash Dividend 
Ex. DateNov 3, 2022

Interim • Div/Share: ₹ 0.8

See all events